Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Retained Earnings over the past 12 years, most recently at -$1.3 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.3 billion for Q4 2025, down 34.41% from a year ago — trailing twelve months through Dec 2025 was -$1.3 billion (down 34.41% YoY), and the annual figure for FY2025 was -$1.3 billion, down 34.41%.
  • Retained Earnings for Q4 2025 was -$1.3 billion at Viridian Therapeutics, Inc.\DE, down from $363000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for VRDN hit a ceiling of $363000.0 in Q3 2025 and a floor of -$1.3 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$322.4 million (2021), compared with a mean of -$392.1 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 186.67% in 2023 and later tumbled 294732.25% in 2024.
  • Viridian Therapeutics, Inc.\DE's Retained Earnings stood at -$358.3 million in 2021, then soared by 99.89% to -$390000.0 in 2022, then skyrocketed by 186.67% to $338000.0 in 2023, then tumbled by 294732.25% to -$995.9 million in 2024, then plummeted by 34.41% to -$1.3 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.3 billion (Q4 2025), $363000.0 (Q3 2025), and -$1.2 billion (Q2 2025) per Business Quant data.